CPIC Profile

Clinical Pharmacogenetics Implementation Consortium

The Clinical Pharmacogenetics Implementation Consortium (CPIC) was formed in late 2009, as a shared project between PharmGKB and the Pharmacogenomics Research Network. CPIC guidelines are peer-reviewed and published in a leading journal (in partnership with Clinical Pharmacology and Therapeutics) with simultaneous posting to PharmGKB with supplemental information/data and updates. Anyone with clinical interests in pharmacogenetics is eligible for membership. CPIC's goal is to address some of the barriers to implementation of pharmacogenetic tests into clinical practice.

BACKGROUND

One barrier to clinical implementation of pharmacogenetics is the lack of freely available, peer-reviewed, updatable, and detailed gene/drug clinical practice guidelines. CPIC provides guidelines that enable the translation of genetic laboratory test results into actionable prescribing decisions for specific drugs. The guidelines can center on genes (e.g. thiopurine methyltransferase and its implications for thiopurines) or around drugs (e.g. warfarin and CYP2C9 and VKORC1). Priority is given to genotyping tests that are already offered in CLIA-approved clinical settings.

CPIC GUIDELINES

CPIC guidelines are designed to help clinicians understand HOW available genetic test results should be used to optimize drug therapy, rather than WHETHER tests should be ordered. A key assumption underlying the CPIC guidelines is that clinical high-throughput and pre-emptive (pre-prescription) genotyping will become more widespread, and that clinicians will be faced with having patients' genotypes available even if they have not explicitly ordered a test with a specific drug in mind. Each CPIC guideline adheres to a standard format, and includes a standard system for grading levels of evidence linking genotypes to phenotypes, how to assign phenotypes to clinical genotypes, dosing recommendations based on genotype/phenotype, and a standard system for assigning strength to each dosing recommendation.

View the current list of gene/drug pairs that are already or will be the subject of CPIC guidelines.

CPIC MEMBERSHIP

CPIC welcomes other national and international groups to assist with the clinical implementation of pharmacogenetics. If you are interested in joining the consortium, please review the Memorandum of Understanding for Members and the Memorandum of Understanding for Publications, then send an email to feedback@pharmgkb.org.

CPIC Team

Consortium Members (Alphabetical by Institution)

• Academic Sinica, Taiwan
  Ming-Ta M. Lee

• Baylor College of Medicine
  Michael Metzker, Steven Scherer

• Cedars-Sinai, Medical Center
  Frank Ong

• Cedars-Sinai, Medical Genetics Institute
  Jerome Rotter

• Children's Mercy Hospital
  Andrea Gaedigk

• Cleveland Clinic
  Kathryn A. Teng, Thomas Daly

• Dartmouth College
  Lionel Lewis

• Indiana University
  Todd Skaar, Tom Callaghan

• *Instituto Nacional de Câncer *
  Guilherme Suarez-Kurtz

• Institute of Biomedical Sciences, TW
  Michael Lee

• Labanese American University, Lebanon
  Yolande Saab

• Leiden University Medical Center
  Henk-Jan Guchelaar, Jesse J. Swen

• "Luigi Sacco" University Hospital, Italy
  Renato Colognato

• Mayo Clinic College of Medicine
  Matthew Goetz, Robert Freimuth, Jyoti Pathak, Christopher G. Chute

• Medco Health Solutions, Inc.
  Felix Frueh, Lynn Wachtel

• Medical College of Wisconsin
  Uli Broeckel

• Mount Sinai Medical School
  Stuart Scott

• Ohio State University
  Wolfgang Sadee, Audrey Papp, Mitch Phelps

• Pharmacogenomics Centre
  Michael Phillips

• SRI International
  Andrew W. Bergen

• St. Jude Children's Research Hospital
  Mary V. Relling, James M. Hoffman, Kristine Crews, Fran Greeson, Mark Dunnenberger

• Stanford University
  Russ B. Altman, Michelle Whirl Carrillo, Teri E. Klein, Caroline Thorn

• The Cleveland Clinic
  Thomas Daly

• University of Alabama
  Nita Limdi

• University of California, San Diego
  Grace M. Kuo

• University of California, San Francisco
  Sook Wah Yee, Jaekyu Shin, Ogechi Ikediobi, Wendy Lorizio, Michael Martin, Deanna Kroetz

• University of Chicago
  M. Eileen Dolan, Peter H. O'Donnell, Nancy Cox, Tamiko Charley

• University of Extremadura, Spain
  José A.G. Agúndez

• University of Florida
  Julie A. Johnson

• University of Houston
  Amalia M. Issa

• University of Liverpool
  Munir Pirmohamed

• University of Manchester
  William Newman

• University of Maryland
  Alan Shuldiner

• University of North Carolina, Chapel Hill
  Howard L. McLeod

• University of Pennsylvania
  Caryn Lerman, Falk Lohoff

• University of Pittsburgh
  Eric E. Gardner

• University of Toronto
  James L. Kennedy, Daniel J. M ü ller, Rachel F. Tyndale

• Uppsala University
  Mia Wadelius

• Vanderbilt University
  Christie Ingram, Marylyn Ritchie, Dan M. Roden, Charles M. Stein, Russell A. Wilke

• Veterans Affairs San Diego Healthcare System
  Susan G. Leckband, Christine Ngyuen, Margaret Mendes

• Washington University in St. Louis
  Brian F. Gage

Observers

• NIH/National Human Genome Research Institute
  Lucia Hindorff, Teri Manolio, Simona Volpi

• NIH/National Institute of General Medical Sciences
  Rochelle M. Long

• NIH/National Heart, Lung, and Blood Institute
  Dina N. Paltoo

• NIH/Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Zhaoxia Ren

• NIH/National Institute on Drug Abuse
  Kristopher Bough

• U.S. Food and Drug Administration
  Issam Zineh

Working Group Site